14.1 USP <800> & NIOSH Hazardous Drug Standards

14.1 USP <800> & NIOSH Hazardous Drug Standards

Occupational exposure to antineoplastic and other hazardous medications represents one of the most critical health and safety challenges in oncology practice. Decades of epidemiological and biological monitoring studies have demonstrated that healthcare personnel—including pharmacists, pharmacy technicians, oncology nurses, shipping and receiving staff, and environmental services workers—routinely face occupational risks from airborne vapors, aerosols, dermal absorption, and surface contamination. Uncontrolled exposure has been causally linked to acute toxicities (skin rashes, hair loss, nausea), chronic organ damage, genotoxic alterations (chromosomal aberrations, sister chromatid exchanges), adverse reproductive outcomes (spontaneous abortions, congenital malformations, fetal loss, infertility), and secondary malignancies (leukemias and lymphomas).

To establish comprehensive, legally enforceable containment standards, the United States Pharmacopeial Convention developed USP General Chapter <800> "Hazardous Drugs—Handling in Healthcare Settings." Board-Certified Oncology Pharmacists (BCOP) must thoroughly understand the regulatory scope of USP <800>, the National Institute for Occupational Safety and Health (NIOSH) categorization framework, facility-specific list maintenance, the Assessment of Risk (AoR) algorithm, and mandatory medical surveillance requirements.

---

1. Regulatory Framework & Interplay of USP Compounding Chapters

USP <800> operates in direct synergy with other foundational compounding and handling chapters within the United States Pharmacopeia. While earlier chapters focus primarily on product quality and patient safety, USP <800> is uniquely engineered to protect occupational personnel, the patient, and the healthcare environment.

+---------------------------------------------------------------------------------------------------+
|                         INTERPLAY OF USP COMPOUNDING & HANDLING CHAPTERS                          |
|                                                                                                   |
|   [USP <795>] Non-Sterile Compounding                                                             |
|   - Focus: Product sterility is NOT required; ensures chemical potency, purity, beyond-use dates |
|   - HD Overlap: When compounding non-sterile HDs, USP <800> containment rules apply              |
|                                                                                                   |
|   [USP <797>] Sterile Compounding                                                                 |
|   - Focus: Product sterility, microbial contamination prevention, environmental ISO cleanliness   |
|   - HD Overlap: When compounding sterile HDs, BOTH USP <797> (sterility) and USP <800>           |
|     (containment) standards must be simultaneously satisfied                                      |
|                                                                                                   |
|   [USP <800>] Hazardous Drugs — Handling in Healthcare Settings                                   |
|   - Focus: OCCUPATIONAL & ENVIRONMENTAL PROTECTION across the entire medication lifecycle         |
|   - Enforceability: Applies to ALL healthcare settings and personnel handling HDs (receipt,      |
|     storage, compounding, transport, dispensing, administration, deactivation, waste disposal)    |
|                                                                                                   |
|   [USP <825>] Radiopharmaceuticals                                                                |
|   - Focus: Handling, compounding, and dispensing of radioactive materials and radiolabeled HDs   |
+---------------------------------------------------------------------------------------------------+

Regulatory Enforceability & Jurisdiction

• State Boards of Pharmacy: Directly enforce USP standards through state pharmacy practice acts, administrative codes, and routine facility inspections.
• Food and Drug Administration (FDA): Enforces compliance under Sections 503A (traditional compounding pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
• Occupational Safety and Health Administration (OSHA): Enforces safe workplace environments under the General Duty Clause (Section 5(a)(1)) and the Hazard Communication Standard (29 CFR 1910.1200), utilizing USP <800> and NIOSH alerts as established industry consensus standards.
• Accreditation Organizations: The Joint Commission (TJC), DNV GL Healthcare, and ACHC inspect healthcare facilities for strict compliance with USP <800> policies and procedures.

---

2. NIOSH Hazardous Drug Definition & Toxicity Criteria

The National Institute for Occupational Safety and Health (NIOSH), a research agency within the Centers for Disease Control and Prevention (CDC), establishes the scientific criteria used to define hazardous drugs. Under the NIOSH definition, a drug is classified as hazardous if, in animal or human studies, it exhibits one or more of the following six toxicity characteristics:

+---------------------------------------------------------------------------------------------------+
|                              NIOSH SIX HAZARDOUS DRUG TOXICITY CRITERIA                           |
|                                                                                                   |
|   1. CARCINOGENICITY:                                                                             |
|      Ability to induce cancer or increase the incidence of benign/malignant neoplasms.             |
|      Examples: Alkylating agents (Cyclophosphamide, Melphalan, Busulfan), Etoposide.              |
|                                                                                                   |
|   2. TERATOGENICITY OR DEVELOPMENTAL TOXICITY:                                                    |
|      Ability to cause structural malformations, fetal growth retardation, or developmental arrest.|
|      Examples: Thalidomide, Lenalidomide, Pomalidomide, Methotrexate, Retinoids.                  |
|                                                                                                   |
|   3. REPRODUCTIVE TOXICITY:                                                                       |
|      Impairment of fertility, gonadal dysfunction, menstrual irregularities, or embryo lethality. |
|      Examples: Ganciclovir, Ribavirin, Tamoxifen, Finasteride, Dutasteride.                       |
|                                                                                                   |
|   4. ORGAN TOXICITY AT LOW DOSES:                                                                 |
|      Significant organ toxicity observed at doses <=10 mg/day or <=1 mg/kg/day in animal models.  |
|      Examples: Cyclosporine, Tacrolimus, Mycophenolate mofetil, Azathioprine.                     |
|                                                                                                   |
|   5. GENOTOXICITY:                                                                                |
|      Ability to damage DNA structures, induce mutations, or cause chromosomal aberrations.         |
|      Examples: Cisplatin, Carboplatin, Carmustine, Fluorouracil, Doxorubicin.                     |
|                                                                                                   |
|   6. STRUCTURE AND TOXICITY MIMICRY:                                                              |
|      New chemical entities possessing molecular structures and toxicity profiles that closely     |
|      resemble existing hazardous agents (e.g., novel kinase inhibitors, modified antimetabolites).|
+---------------------------------------------------------------------------------------------------+

---

3. NIOSH Hazardous Drug Categorization Groups

NIOSH maintains and periodically updates a comprehensive list of hazardous drugs used in healthcare settings, stratifying agents into three operational groups:

---

4. Facility-Specific HD List & The Assessment of Risk (AoR)

Entity-Specific Hazardous Drug List Requirements

Under USP <800>, each healthcare institution must establish, maintain, and document its own facility-specific hazardous drug list. This list must include:

1. All items on the current NIOSH list that the facility receives, stocks, compounds, dispenses, or administers.
2. Any newly FDA-approved drugs or investigational drugs entering the formulary that meet NIOSH hazardous criteria.
3. Annual Mandatory Review: The list must be reviewed and documented at least once every 12 months (or whenever a new agent or dosage form is introduced) by the Designated Person.

The "Designated Person" Role

USP <800> mandates that every entity handling hazardous drugs must assign one or more qualified individuals as the Designated Person. The Designated Person is formally responsible for:

• Developing, approving, implementing, and enforcing standard operating procedures (SOPs).
• Ensuring continuous compliance with USP <800>, state, and federal containment mandates.
• Overseeing environmental monitoring, facility engineering maintenance, and certification.
• Supervising personnel training, initial and annual competency evaluations, and medical surveillance.

Assessment of Risk (AoR) Decision Algorithm

USP <800> allows healthcare entities to perform a documented Assessment of Risk (AoR) to evaluate whether certain hazardous drug dosage forms may be handled with alternative containment strategies rather than full engineering controls.

+---------------------------------------------------------------------------------------------------+
|                         USP <800> ASSESSMENT OF RISK (AoR) DECISION ALGORITHM                     |
|                                                                                                   |
|   IS THE DRUG AN ACTIVE PHARMACEUTICAL INGREDIENT (API) OF ANY HAZARDOUS DRUG?                     |
|         |                                                                                         |
|         +---> [YES] ================================> MUST FOLLOW FULL USP <800> CONTAINMENT!     |
|         |                                             (C-PEC, C-SEC, Storage, Full PPE)           |
|         +---> [NO]                                    (NO AoR EXEMPTION ALLOWED!)                 |
|                 |                                                                                 |
|                 v                                                                                 |
|   IS IT AN ANTINEOPLASTIC DRUG REQUIRING MANIPULATION?                                            |
|   (e.g., Compounding IV solutions, crushing tablets, opening capsules, reconstituting powders)      |
|         |                                                                                         |
|         +---> [YES] ================================> MUST FOLLOW FULL USP <800> CONTAINMENT!     |
|         |                                             (C-PEC, C-SEC, Storage, Full PPE)           |
|         +---> [NO]                                    (NO AoR EXEMPTION ALLOWED!)                 |
|                 |                                                                                 |
|                 v                                                                                 |
|   IS IT AN INTACT FINISHED DOSAGE FORM OR GROUP 2 / GROUP 3 HAZARDOUS DRUG?                       |
|   (e.g., Counting intact unit-dose oral tablets, administering pre-packaged oral liquid/capsule)  |
|         |                                                                                         |
|         +---> [YES] --------------------------------> ELIGIBLE FOR ASSESSMENT OF RISK (AoR)       |
|                                                       - Evaluate drug type, dosage form, packaging|
|                                                       - Define alternative containment strategies |
|                                                       - Document and review AoR every 12 months!  |
+---------------------------------------------------------------------------------------------------+

Alternative Containment Strategies Under AoR

When an AoR is performed for eligible intact dosage forms (e.g., counting intact tablets of spironolactone, methotrexate, or capecitabine), the facility may establish alternative SOPs:

• Dedicated Equipment: Utilizing dedicated counting trays, spatulas, and automated dispensing cells marked exclusively for hazardous drugs, thoroughly cleaned with deactivating agents after each use.
• Automated Counting Restrictions: Prohibiting the use of high-speed automated pill counters/counting robots that create airborne dust or particulate friction.
• Packaging & Enclosure: Dispensing medications in unit-dose packaging or sealed plastic pouches to eliminate subsequent handling manipulation by bedside nurses.
• Personal Protective Equipment: Requiring a single pair of chemotherapy-tested gloves (ASTM D6978) during counting and packaging operations.

---

5. Personnel Training, Competencies & Medical Surveillance

+---------------------------------------------------------------------------------------------------+
|                         USP <800> PERSONNEL TRAINING & COMPETENCY TIMELINE                        |
|                                                                                                   |
|   [INITIAL ONBOARDING]                                                                            |
|   - Prior to independently handling any hazardous drug                                            |
|   - Didactic instruction on HD list, risks, SDS interpretation, SOPs, and engineering controls    |
|   - Practical demonstration: Donning/doffing PPE, aseptic manipulation, CSTD use, spill response   |
|   - Documented signature acknowledging reproductive and occupational health risks                 |
|                                   |                                                               |
|                                   v                                                               |
|   [RECURRENT ANNUAL COMPETENCY]                                                                   |
|   - Documented reassessment at least once every 12 months                                         |
|   - Gloved fingertip testing & media-fill simulation (if performing sterile HD compounding)        |
|                                   |                                                               |
|                                   v                                                               |
|   [TRIGGER-BASED RE-TRAINING]                                                                     |
|   - Introduction of a new hazardous agent, novel equipment (C-PEC/CSTD), or updated SOP           |
|   - Following an accidental spill, occupational exposure incident, or environmental failure       |
+---------------------------------------------------------------------------------------------------+

Occupational Medical Surveillance Program

USP <800> recommends and professional guidelines mandate a structured medical surveillance program to monitor personnel who handle hazardous drugs on a regular basis. The program serves as a secondary line of defense to identify early biological effects or system failures:

1. Baseline Health Assessment: Comprehensive occupational history, medical/reproductive history, physical examination, and baseline laboratory panels (Complete Blood Count [CBC] with differential, comprehensive metabolic panel [CMP] for hepatic and renal indices, and baseline urinalysis).
2. Ongoing Health Surveillance: Periodic health evaluations, tracking of acute exposure symptoms (dizziness, nausea, skin rashes, mucosal irritation), and recording of reproductive outcomes.
3. Post-Exposure & Incident Protocol: Immediate clinical evaluation, decontamination, lab testing, root-cause investigation, and documentation following acute spills, needle-sticks, or splash injuries.
4. Exit Examination: Documentation of overall health status and cumulative occupational exposure history upon termination of employment or reassignment away from hazardous handling areas.